Compounded GLP-1 and the Big Telehealth Brands: What Changed in 2026

In 2026, several large telehealth companies scaled back or changed how they offer compounded GLP-1 medications, shifting the landscape for patients who had relied on them. The underlying reasons tie to evolving supply and regulatory conditions around compounded GLP-1 formulations. For eligible patients, compounded options remain available through providers that continue to offer them — including Vyvron, which continues to connect eligible patients with licensed providers. Compounded medications are not FDA-approved.

What actually changed

The compounded GLP-1 market in 2026 looks different than it did a year earlier. Several large players in the space adjusted their programs — in some cases reducing compounded offerings, in others moving patients toward different options. Rather than cite specific companies or dates we can't source precisely, the fair summary is this: the field consolidated, and some of the biggest names stepped back from the compounded lane. If a provider you previously used changed or discontinued its compounded program, you are not alone, and it does not mean compounded GLP-1 is universally unavailable.

Why this happened (at a high level)

Compounded GLP-1 access has always been tied to specific supply and regulatory conditions rather than being a permanent fixture. When those conditions shift, providers reassess whether and how to offer compounded formulations. Large, multi-product telehealth companies in particular tend to adjust their catalogs in response to those changes. The net effect in 2026 was a narrower set of large brands actively offering compounded GLP-1 than at the category's peak. Importantly, none of this changes the two facts a patient should hold onto: Compounded medications are not FDA-approved, and that has always been true. Legitimacy depends on the provider and pharmacy, not on brand size.

What it means for access

If a large brand you used scaled back, here is the practical takeaway. Compounded options still exist through providers that continue to offer them. Size is not a proxy for trust — a smaller provider that is LegitScript-certified, uses licensed providers who review every request, and dispenses from a licensed US pharmacy can be a sound choice. Vet before you switch: the checklist is the same regardless of which provider left the space — certification, a licensed provider reviewing every request, a licensed US pharmacy, and transparent pricing.

Where eligible patients can continue

Vyvron continues to connect eligible patients with licensed providers for compounded options. The model is deliberately simple and transparent. A licensed provider reviews every request before anything is prescribed. Medication ships from a licensed US pharmacy. Pricing is published: a founding-member rate of $199 for the first month, returning to a regular rate of $249, billed every 4 weeks, cancel anytime with cancellation taking effect at the end of your billing cycle and no fees. Eligibility for weight management is a BMI of 27+ (or 25+ with a related condition). Vyvron is LegitScript-certified and accepts HSA/FSA, Visa, Mastercard, Apple Pay, and Google Pay (not American Express). It does not promise any specific medication or outcome — availability is a clinical decision based on medical necessity.

See if you qualify